Citigroup Downgrades Silk Road Medical to Sell, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Sell and lowered the price target from $35 to $8.

October 11, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Silk Road Medical's stock has been downgraded by Citigroup from Buy to Sell, with a significant reduction in price target from $35 to $8.
The downgrade from Buy to Sell by Citigroup, a major financial institution, is a strong negative signal for Silk Road Medical. The drastic reduction in price target from $35 to $8 further indicates a bearish outlook for the company's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100